Tekla Capital Management: Funding, Team & Investors

Tekla Capital Management operates as an investment advisory firm, primarily managing closed-end funds dedicated to the healthcare and life sciences sectors. Its core product involves constructing diversified portfolios of publicly traded companies within biotechnology, pharmaceuticals, medical devices, and healthcare services, employing deep sector expertise to identify promising growth opportunities and manage risk within this specialized industry.

Established in 1986, Tekla Capital Management was founded with the strategic insight that focused investment vehicles could unlock value by specializing in dynamic, innovation-driven sectors. The firm was built as an employee-owned investment manager, fostering a culture of specialized research and long-term capital stewardship, particularly within the evolving landscape of medical and scientific discovery.

The funds advised by Tekla Capital Management cater to a broad base of institutional and individual investors seeking targeted exposure to the healthcare and life sciences markets. The firm’s vision revolves around navigating and capitalizing on ongoing advancements and disruptive trends within these vital sectors, aiming to generate long-term capital appreciation for its shareholders by supporting companies at the forefront of medical innovation.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 1, 2023	Amolyt Pharma	$140.0M Series C	Toby Sykes, Cédric Moreau	Andera Partners, Bioqube Ventures, Domain Associates, EQT Life Sciences, Forbion, Kurma Partners, Pontifax Venture Capital, Sanofi Ventures, Ysios Capital, Vincent Brichard, Atem Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, LSP, Mass General Brigham Ventures, Novo Holdings, OrbiMed, Relyens Innovation Sant, Sectoral Asset Management
May 1, 2022	Invetx	$61.0M Series B	Eight Roads Ventures, Jessica Alston, GV, Novo Holdings	Anterra Capital, F Prime Capital, Casdin Capital
Feb 1, 2022	Endeavor BioMedicines	$100.0M Series B	Andrew LAM, TriWise Capital, Monal Mehta	Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Patrick Enright, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, T. Rowe Price Associates
Nov 9, 2021	Arbor Biotechnologies	$215.0M Series B	Frank YU, Chen YU, Temasek	ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, ONO Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, TAO Capital Partners, T. Rowe Price Associates, Vertex, Woodline Partners
Nov 3, 2021	Parthenon Therapeutics	$65.0M Series A	Northpond Ventures, Taiho Ventures	Alexandria Venture Investments, Breakout Ventures, Creacion Ventures, KDT Ventures, Park West Asset Management, Section 32
Nov 1, 2021	HotSpot Therapeutics	$100.0M Series C	Pivotal BioVenture Partners	AbbVie Ventures, Access Biotechnology, Atlas Venture, EQT Life Sciences, Novo Ventures, Rivervest, Roche Venture Fund, Samsara BioCapital, Soffinova Partners, SR ONE, B Capital Group, Caas Capital Management, Fouad Azzam, Ph.D., Monashee Investment Management, MRL Ventures Fund, Pavilion Capital, Revelation Partners
Nov 1, 2021	Quell Therapeutics	$160.0M Series B	Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian	Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy
Oct 1, 2021	ReCode Therapeutics	$80.0M Series B	Oleg Nodelman	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, SAM Altman, Colt Ventures, Hunt Technology Ventures, NS Investment, Osage University Partners, Sanofi Ventures, Superstring Capital
Jun 1, 2021	ImmuneID	$50.0M Series A	Alta Partners	Advanced Technology Ventures, Aisling Capital, Chris, Domain Associates, Longwood Fund, Section 32, The Column Group, Third Rock Ventures, Alexandria Venture Investments, ARCH Venture Partners, IN Q TEL, Pitango HealthTech, Redwood Capital Investments, Xfund
May 22, 2021	HiberCell	$97.4M Debt / Series B	—	ARCH Venture Partners, Bristol Myers Squibb, Hercules Capital, Huizenga Capital Management, Magnetic Ventures, Rene Mora, Mount Sinai Innovation Partners, Trinitas Capital
May 20, 2021	Biotheryx	$92.0M Series E	Farallon Capital Management	Alexandria Venture Investments, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Wedbush Healthcare Partners
May 1, 2021	Oculis	$57.0M Series C	Bvcf (bioveda China Fund), DR. Sylvia XIN HE	ZHI Yang, Kiersten Stead, Dimension Capital, Earlybird Venture Capital, Eclipse Ventures, EQT Life Sciences, Longitude Capital, Maveron, NEW Enterprise Associates (NEA), OrbiMed, Peterson Ventures, Pivotal BioVenture Partners, The Column Group, Farzad Nazem, BAY City Capital, Brunnur Ventures, NAN Fung Life Sciences, Novartis, Silfurberg, VI Partners, Wille Finance
Mar 1, 2021	Pyxis Oncology	$150.0M Series B	Christian Schetter, Gotham Makker	Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps BY Bayer, Lifesci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Ridgeback Capital Investments, Surveyor Capital
Mar 1, 2021	Caribou Biosciences	$120.0M Series C	Farallon Capital Management, Santhosh Palani, Phd, CFA, Jeffrey Long Mcgie	1435 Capital Management, 6TH MAN Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co OP, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William GUO, Xstarpartners, Adam Marchick, Andy Rubin, Dylan Taylor, Hugo Angelmar, Ravi Grover, Richard Cooperstein, ROB Meyerson, SRI Batchu, Sung HO Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, Lifesci Venture Partners, Monashee Investment Management, Point72, Pontifax, The Leukemia & Lymphoma Society
Sep 1, 2020	Invetx	$10.0M Series A	Anterra Capital	AbCellera, Casdin Capital, WuXi Biologics
Apr 1, 2020	Rallybio	$150.0M Series B	Pivotal BioVenture Partners	Canaan Partners, HealthQuest Capital, Sofinnova Investments, 5AM Ventures, Canaan Partners, Connecticut Innovations, Fairview Capital, F Prime Capital, Mitsui & CO. Global Investment, NEW Leaf Venture Partners, Solasta Ventures, TPG, Viking Global Investors
Nov 1, 2019	Arkuda Therapeutics	$44.0M Series A	Atlas Venture	EQT Life Sciences, Pivotal BioVenture Partners, Soffinova Partners, SR ONE, Mission BioCapital
Sep 24, 2019	Amphivena Therapeutics	$62.0M Series C	NanoDimension, Qiming Venture Partners USA	Franklin Berger, AJU IB Investment, Industrial Investors, Kaitai Capital, Korys Merieux, MPM Capital, Nawton Limited
Oct 25, 2018	Milestone Pharmaceuticals	$80.0M Other Equity	RTW Investments	BDC Capital, Boxer Capital, Domain Associates, Forbion, GO Capital, Novo Holdings, Pappas Capital, Venrock
Oct 1, 2018	Milestone Pharmaceuticals	$80.0M Series D	RTW Investments	BDC Venture Capital, Domain Associates, Forbion, Mission BioCapital, BDC Capital, Boxer Capital, Fonds DE Solidarit FTQ, GO Capital, Novo Holdings, Pappas Capital, Venrock
Sep 12, 2018	Atreca	$125.0M Series C	—	Aisling Capital, Boxer Capital, Cormorant Asset Management, EcoR1 Capital, Redmile Group, Samsara BioCapital, Wellington Management
Sep 1, 2018	Galera Therapeutics	$70.0M Series C	Emmett Cunningham	NanoDimension, James Barrett, Adage Capital Management, Correlation Ventures, Galera Angels, HBM Healthcare Investments, NAN Fung Life Sciences, NEW Enterprise Associates, Novartis, Novo Ventures, RA Capital Management, Rock Springs Capital, Sofinnova Investments
Aug 9, 2018	Therachon	$60.0M Debt	Jørgen Søberg Petersen	Bpifrance, TIM Anderson, Inserm Transfert Initiative, OrbiMed, TOM Woiwode
Aug 1, 2018	Therachon	$60.0M Series B	Novo Holdings	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Versant Ventures, Bpifrance, Cowen Healthcare Investments, Inserm Transfert Initiative, Pfizer Ventures
Jul 1, 2018	Sutro	$85.0M Series E	Samsara BioCapital, Surveyor Capital	Advent Life Sciences, Alta Partners, Amgen Ventures, Celgene, Eventide Asset Management, Lilly Ventures, Merck, Nexthera Capital, Skyline Ventures, SV Health Investors, Vida Ventures

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 1, 2023	Amolyt Pharma	$140.0M Series C	Toby Sykes, Cédric Moreau	Andera Partners, Bioqube Ventures, Domain Associates, EQT Life Sciences, Forbion, Kurma Partners, Pontifax Venture Capital, Sanofi Ventures, Ysios Capital, Vincent Brichard, Atem Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, LSP, Mass General Brigham Ventures, Novo Holdings, OrbiMed, Relyens Innovation Sant, Sectoral Asset Management
May 1, 2022	Invetx	$61.0M Series B	Eight Roads Ventures, Jessica Alston, GV, Novo Holdings	Anterra Capital, F Prime Capital, Casdin Capital
Feb 1, 2022	Endeavor BioMedicines	$100.0M Series B	Andrew LAM, TriWise Capital, Monal Mehta	Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Patrick Enright, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, T. Rowe Price Associates
Nov 9, 2021	Arbor Biotechnologies	$215.0M Series B	Frank YU, Chen YU, Temasek	ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, ONO Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, TAO Capital Partners, T. Rowe Price Associates, Vertex, Woodline Partners
Nov 3, 2021	Parthenon Therapeutics	$65.0M Series A	Northpond Ventures, Taiho Ventures	Alexandria Venture Investments, Breakout Ventures, Creacion Ventures, KDT Ventures, Park West Asset Management, Section 32
Nov 1, 2021	HotSpot Therapeutics	$100.0M Series C	Pivotal BioVenture Partners	AbbVie Ventures, Access Biotechnology, Atlas Venture, EQT Life Sciences, Novo Ventures, Rivervest, Roche Venture Fund, Samsara BioCapital, Soffinova Partners, SR ONE, B Capital Group, Caas Capital Management, Fouad Azzam, Ph.D., Monashee Investment Management, MRL Ventures Fund, Pavilion Capital, Revelation Partners
Nov 1, 2021	Quell Therapeutics	$160.0M Series B	Fidelity Management & Research Company, Rachel Mears, Wayne Holman, Houman Ashrafian	Lightstone Ventures, Soffinova Partners, SV Health Investors, Judith Hartley MBE, Janus Henderson Investors, Monashee Investment Management, Point72, Martin Murphy
Oct 1, 2021	ReCode Therapeutics	$80.0M Series B	Oleg Nodelman	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, SAM Altman, Colt Ventures, Hunt Technology Ventures, NS Investment, Osage University Partners, Sanofi Ventures, Superstring Capital
Jun 1, 2021	ImmuneID	$50.0M Series A	Alta Partners	Advanced Technology Ventures, Aisling Capital, Chris, Domain Associates, Longwood Fund, Section 32, The Column Group, Third Rock Ventures, Alexandria Venture Investments, ARCH Venture Partners, IN Q TEL, Pitango HealthTech, Redwood Capital Investments, Xfund
May 22, 2021	HiberCell	$97.4M Debt / Series B	—	ARCH Venture Partners, Bristol Myers Squibb, Hercules Capital, Huizenga Capital Management, Magnetic Ventures, Rene Mora, Mount Sinai Innovation Partners, Trinitas Capital
May 20, 2021	Biotheryx	$92.0M Series E	Farallon Capital Management	Alexandria Venture Investments, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Wedbush Healthcare Partners
May 1, 2021	Oculis	$57.0M Series C	Bvcf (bioveda China Fund), DR. Sylvia XIN HE	ZHI Yang, Kiersten Stead, Dimension Capital, Earlybird Venture Capital, Eclipse Ventures, EQT Life Sciences, Longitude Capital, Maveron, NEW Enterprise Associates (NEA), OrbiMed, Peterson Ventures, Pivotal BioVenture Partners, The Column Group, Farzad Nazem, BAY City Capital, Brunnur Ventures, NAN Fung Life Sciences, Novartis, Silfurberg, VI Partners, Wille Finance
Mar 1, 2021	Pyxis Oncology	$150.0M Series B	Christian Schetter, Gotham Makker	Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Laurion Capital Management, Leaps BY Bayer, Lifesci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Ridgeback Capital Investments, Surveyor Capital
Mar 1, 2021	Caribou Biosciences	$120.0M Series C	Farallon Capital Management, Santhosh Palani, Phd, CFA, Jeffrey Long Mcgie	1435 Capital Management, 6TH MAN Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co OP, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William GUO, Xstarpartners, Adam Marchick, Andy Rubin, Dylan Taylor, Hugo Angelmar, Ravi Grover, Richard Cooperstein, ROB Meyerson, SRI Batchu, Sung HO Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, Lifesci Venture Partners, Monashee Investment Management, Point72, Pontifax, The Leukemia & Lymphoma Society
Sep 1, 2020	Invetx	$10.0M Series A	Anterra Capital	AbCellera, Casdin Capital, WuXi Biologics
Apr 1, 2020	Rallybio	$150.0M Series B	Pivotal BioVenture Partners	Canaan Partners, HealthQuest Capital, Sofinnova Investments, 5AM Ventures, Canaan Partners, Connecticut Innovations, Fairview Capital, F Prime Capital, Mitsui & CO. Global Investment, NEW Leaf Venture Partners, Solasta Ventures, TPG, Viking Global Investors
Nov 1, 2019	Arkuda Therapeutics	$44.0M Series A	Atlas Venture	EQT Life Sciences, Pivotal BioVenture Partners, Soffinova Partners, SR ONE, Mission BioCapital
Sep 24, 2019	Amphivena Therapeutics	$62.0M Series C	NanoDimension, Qiming Venture Partners USA	Franklin Berger, AJU IB Investment, Industrial Investors, Kaitai Capital, Korys Merieux, MPM Capital, Nawton Limited
Oct 25, 2018	Milestone Pharmaceuticals	$80.0M Other Equity	RTW Investments	BDC Capital, Boxer Capital, Domain Associates, Forbion, GO Capital, Novo Holdings, Pappas Capital, Venrock
Oct 1, 2018	Milestone Pharmaceuticals	$80.0M Series D	RTW Investments	BDC Venture Capital, Domain Associates, Forbion, Mission BioCapital, BDC Capital, Boxer Capital, Fonds DE Solidarit FTQ, GO Capital, Novo Holdings, Pappas Capital, Venrock
Sep 12, 2018	Atreca	$125.0M Series C	—	Aisling Capital, Boxer Capital, Cormorant Asset Management, EcoR1 Capital, Redmile Group, Samsara BioCapital, Wellington Management
Sep 1, 2018	Galera Therapeutics	$70.0M Series C	Emmett Cunningham	NanoDimension, James Barrett, Adage Capital Management, Correlation Ventures, Galera Angels, HBM Healthcare Investments, NAN Fung Life Sciences, NEW Enterprise Associates, Novartis, Novo Ventures, RA Capital Management, Rock Springs Capital, Sofinnova Investments
Aug 9, 2018	Therachon	$60.0M Debt	Jørgen Søberg Petersen	Bpifrance, TIM Anderson, Inserm Transfert Initiative, OrbiMed, TOM Woiwode
Aug 1, 2018	Therachon	$60.0M Series B	Novo Holdings	5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Versant Ventures, Bpifrance, Cowen Healthcare Investments, Inserm Transfert Initiative, Pfizer Ventures
Jul 1, 2018	Sutro	$85.0M Series E	Samsara BioCapital, Surveyor Capital	Advent Life Sciences, Alta Partners, Amgen Ventures, Celgene, Eventide Asset Management, Lilly Ventures, Merck, Nexthera Capital, Skyline Ventures, SV Health Investors, Vida Ventures

Tekla Capital Management

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Leadership Team

Leadership Team

Leadership Team

Investment Activity

Investments Made